Multiple major M&A activities and bankruptcies dominate the market: Funko surges 25% after investor urges sale exploration; Caesars Entertainment weighs takeover offers including from billionaire Tilman Fertitta; Netflix loses Warner Bros. bidding war to Paramount Skydance's $111B offer; GSK acquires 35Pharma for $950M; and iPic Theaters files for Chapter 11 bankruptcy.

GSK agreed to acquire Canada-based 35Pharma Inc. for $950 million to expand its pulmonary hypertension pipeline with HS235, an investigational medicine targeting the activin receptor signalling pathway. The acquisition comes as GSK also signed a licensing deal with Frontier Biotechnologies and previously agreed to acquire RAPT Therapeutics for $2.2 billion, strengthening its position in the growing PH therapeutics market projected to reach $18 billion by 2032.

GSK has agreed to acquire Canadian biopharmaceutical company 35Pharma for $950 million in cash. The acquisition includes HS235, a clinical-stage investigational medicine designed to treat pulmonary hypertension with reduced bleeding risk and metabolic benefits compared to existing therapies. HS235 has completed Phase I trials and is set to begin studies in pulmonary arterial hypertension and heart failure patients.

The global anti-snoring devices market is expected to grow from $1.81 billion in 2025 to $3.36 billion by 2033, with an 8.04% CAGR. Growth drivers include rising obesity rates, increased awareness of health risks associated with snoring, technological innovations, and improved e-commerce accessibility. Major players like Philips, ResMed, and SomnoMed are leading the market with advanced solutions.

The global sexual health supplement market is projected to grow from $3.79 billion in 2026 to $5.31 billion by 2030 at a CAGR of 8.8%, driven by increased consumer awareness, demand for natural formulations, personalized products, and e-commerce expansion. Key trends include innovative formats like functional gummies, gender-specific supplements, and enhanced ingredient transparency. Asia Pacific leads the market, with major players including Pfizer, GlaxoSmithKline, and Amway.

The release of Epstein files has triggered a major political crisis across Europe, with senior UK officials including Andrew Mountbatten-Windsor arrested and Lord Peter Mandelson resigning. The scandal has roiled UK gilt markets, widening yield spreads and raising borrowing costs, while the UK economy stagnates with only 0.1% Q4 growth. Prime Minister Starmer faces mounting pressure with betting markets pricing a 68% probability he'll leave office by June.

Merck announced positive Phase 3 SMART trial data for Enflonsia (clesrovimab), its RSV monoclonal antibody treatment, showing consistent safety in children under 2 years old. The company is seeking FDA approval to expand the indication to children at increased risk for severe RSV disease for a second RSV season. The data will be submitted to the FDA for evaluation.

The European Commission approved GSK's Exdensur (depemokimab) for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). The approval is based on phase 3 trials showing a 58% and 48% reduction in annualized asthma exacerbations with twice-yearly dosing. GSK stock rose 2.65% to $60.49 in premarket trading.

The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.

The global Hepatitis B treatment market is valued at USD 4.52 billion in 2025 and is projected to reach USD 7.74 billion by 2033, growing at a CAGR of 6.97%. Growth is driven by expanded screening programs, increased antiviral therapy adoption, and novel treatment innovations. The U.S. market is expected to grow from USD 1.00 billion to USD 1.54 billion by 2033.

The global anti-obesity drugs market is estimated at US$22.52 billion in 2026 and is projected to grow at a CAGR of 24.2% to reach US$195.99 billion by 2036, driven by rising obesity rates, improved clinical efficacy of GLP-1 and multi-agonist therapies, and broader recognition of obesity as a chronic disease. However, US trade tariffs are adding cost pressures to pharmaceutical supply chains.

The global teeth whitening products market is projected to grow from US$ 5.2 billion in 2022 to US$ 8.73 billion by 2031, with a CAGR of 6.03%. Growth is driven by increasing aesthetic awareness, social media influence, rising popularity of over-the-counter products, and rapid adoption of at-home whitening solutions. The Asia Pacific region leads the market, while the online segment and household segment are expected to experience the fastest growth.